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Abstract Oxoid Brilliance™ MRSA was evaluated for
its ability to identify methicillin-resistant Staphylococcus
aureus. Awell-defined collection of staphylococci was used
(n=788). After 20 h incubation, the sensitivity was 99.6%
and the specificity was 97.3%. This new medium is a
highly sensitive method of screening for MRSA.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) has
emerged worldwide as a nosocomial pathogen of major
importance, and the incidence of infections caused by
MRSA continues to increase [1, 2]. Recently, MRSA has
emerged in the community [3]. Also a new clone has been
identified that is related to an extensive reservoir in animals.
Persons who are in direct contact with pigs frequently carry
this animal-related MRSA [4, 5]. Laboratory-based screening
for MRSA colonization of patients and health care workers
remains a cornerstone of infection control measures to limit
the spread of this organism [6]. The extension of MRSA
beyond its known boundaries poses an additional challenge
for microbiological laboratories to improve their screening
strategies. Methods of detecting MRSA in clinical samples
ideally should have a high sensitivity and specificity
combined with a short time to reporting of the results. To
identify S. aureus from contaminated samples more easily
and more reliably, selective media have been developed [7].
The purpose of this study was to evaluate the in vitro
sensitivity and specificity of a new selective medium, called
Oxoid Brilliance™ MRSA for the identification of MRSA,
using a well-defined collection of strains.
Materials and methods
A collection consisting of 266 MRSA strains, 257
methicillin-susceptible S. aureus (MSSA) strains, and 265
coagulase-negative staphylococci (CNS) was used. The
collection was described previously [8–10]. In short, the
MRSA isolates were collected in the Netherlands between
1989 and 1998 and were obtained from the MRSA strain
collection of the National Institute of Public Health and
Environmental Protection, Bilthoven, The Netherlands.
Identification of strains as S. aureus and as being
methicillin-resistant was performed by duplex PCR for the
mecA gene and the coagulase gene [11]. Bacteriophage
typing was performed as described previously [12, 13], by
using the international set of phages at 1 and 100 times the
routine test dilution concentrations, an additional set of
Dutch phages, and a set of experimental MRSA phages.
The 266 MRSA isolates included in the study comprised
247 different phage types. Three isolates were not typable.
All clonal lineages were represented with the exception of
the recently emerged animal-related strains, ST398 [4].
CNS strains were confirmed as coagulase-negative using
both DNase test and Remel Staphaurex® Plus. The MSSA
and CNS strains were isolated from cultures of blood from
patients who were admitted to the following hospitals
between January 1996 and May 1999: St. Elisabeth
Hospital and Tweesteden Hospital, Tilburg, the Nether-
lands; Pasteur Hospital, Oosterhout, the Netherlands;
Tweesteden Hospital, Waalwijk, the Netherlands; and
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per patient was included. Isolates were identified by a latex
agglutination test (Staphaurex Plus; Thermo Fisher Scien-
tific, Dartford, UK), by the detection of free coagulase
using a tube coagulase test with rabbit plasma, and by the
detection of DNase (Oxoid DNase agar; Thermo Fisher
Scientific, Basingstoke, UK). If the results of these tests
were discordant, an AccuProbe culture identification test
(Gen-Probe, San Diego, CA, USA) was performed accord-
ing to the manufacturer’s instructions, and this was
considered the “gold standard.” The S. aureus blood culture
isolates were classified as methicillin-susceptible at the time
of collection by broth microdilution susceptibility testing
performed according to CLSI (formerly NCCLS) standards
[14]. The isolates were stored at −70°C until they were
tested.
Oxoid Brilliance™ MRSA is a new chromogenic
medium for identification of MRSA in human specimens
and was supplied as prepoured culture plates from Thermo
Fisher Scientific (Basingstoke, UK). The composition of
the chromogenic and selective mix is proprietary. On Oxoid
Brilliance™ MRSA, MRSA strains form distinctive
denim blue colonies (Fig. 1). The selective mixture inhibits
MSSA strains, most bacteria not belonging to the genus
Staphylococcus, and yeasts. Results can be read after 18 h,
according to the manufacturer. The isolates were inoculated
onto Columbia agar plates with 5% sheep blood and
incubated for 24 h at 35°C. From the resulting cultures, a
suspension of 0.5 McFarland was made, and subsequently,
10 μl was streaked onto an Oxoid Brilliance™ MRSA plate
with a sterile loop using a three-streak dilution method. The
results were read after 20 h of incubation at 35°C. Growth
of colonies showing blue coloration was considered to be
indicative of MRSA. No growth or colonies with colors
other than blue was considered negative. The procedure
was performed as recommended by the manufacturer.
Discordant results of MRSA strains (no growth on Oxoid
Brilliance™ MRSA) were confirmed by mecA gene and
S. aureus PCR as described previously [11]. If the mecA
PCR was negative the strain was removed from the analysis.
Results and discussion
The results obtained with Oxoid Brilliance™ MRSA are
shown in Table 1. In the current evaluation, 29 of the
266 MRSA strains gave discordant results (10.9%).
Subsequently, a PCR for the mecA gene was performed
on these isolates and 28 strains had a negative result. These
28 MRSA strains were removed from the analysis,
according to the protocol. After 20 h incubation the
sensitivity of Oxoid Brilliance™ MRSA was 237 out of
238 (99.6% [95% CI 98.2%–99.9%]) and the specificity
was 508 out of 522 (97.3% [95% CI 96.4%–98.2%]). The
one MRSA strain that did not grow on the Oxoid
Brilliance™ MRSA agar plate was tested for its cefoxitin
susceptibility using disk diffusion. The cefoxitin zone
diameter of this strain was 28 mm, which is considered
susceptible according to the CLSI criteria [14].
Five of the MSSA strains and nine of the CNS strains
also grew blue colonies ranging from light blue through the
typical denim blue color and were reported as positive on
Oxoid Brilliance™ MRSA agar. The five MSSA strains
had cefoxitin zone diameters ranging from 24 to 30 mm,
which is considered susceptible and falls within the
susceptible range of the wild type strains [15]. The false-
positivity rate of Oxoid Brilliance™ MRSA due to MSSA
strains was lower than for CNS (Table 1), but these results
were not statistically significant (P=0.42).
Oxoid Brilliance™ MRSAwas a highly reliable screening
tool for the detection of MRSA. All but one MRSA strain
included in the analysis was detected after 20 h of incubation.
In a recent study, the in vitro sensitivity and specificity of
MRSA ID (bioMérieux, La-Balme-Les-Grottes, France) was
evaluated using the same collection of strains [9]. A total of
251 MRSA strains, 249 MSSA strains, and 478 CNS strains
Fig. 1 Typical color and morphology of MRSA strains on Oxoid
Brilliance™ MRSA plates
Table 1 Results for Oxoid Brilliance™ MRSA medium after 20 h of
incubation
Isolate Number of strains with a positive test
result/total number of strains (%)
MSSA 5/257 (1.9)
CNS 9/265 (3.4)
Total (CNS + MSSA) 14/522 (2.7)
MRSA 237/238 (99.6)
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used in the present evaluation was significantly higher than
MRSA ID in the previous evaluation (99.6% [237 out of
238] vs 96.4% [242 out of 251] respectively, P=0.021). The
specificity of Oxoid Brilliance™ MRSA was lower than that
of MRSA ID (97.3% [508 out of 522] and 98.2% [714 out
of 727] respectively), but this difference was not significant
(P=0.33). In another study, Diederen et al. evaluated the in
vitro sensitivity and specificity of CHROMagar MRSA
(CHROMagar Microbiology, Paris, France), using the same
collection of strains [8]. A total of 216 MRSA strains and
241 MSSA strains were tested. Oxoid Brilliance™ MRSA
medium used in the present evaluation has a higher
sensitivity at 24 h of incubation than CHROMagar MRSA
medium (99.6% [237 out of 238] and 95.4% [206 out of
216] respectively, P=0.004). After 48 h of incubation the
sensitivity of CHROMagar MRSA raised to 100%. The
specificity of Oxoid Brilliance™ MRSA medium, consider-
ing MSSA, was lower at 24 h of incubation than that of
CHROMagar MRSA medium (98.1% [252 out of 257] and
100% [241 out of 241] respectively), but this difference was
not statistically significant (P=0.06).
A remarkable finding is the absence of the mecA gene in
28 MRSA strains. One might speculate that these strains
were not the original strains in the collection. However, we
have shown in a previous evaluation that this was due to
loss of the mecA gene in the freezer. In that study, 36
(14.4%) of 250 methicillin-resistant Staphylococcus aureus
isolates had lost the mecA gene [16]. In the current
evaluation, 28 (10.5%) of 266 previously confirmed MRSA
strains no longer harbored the mecA gene. These findings
have important implications for the management of strain
collections as well as the use of strain collections for an in
vitro evaluation. In order to avoid an underestimation of the
sensitivity of the MRSA screening test under evaluation,
discordant test results must be checked for the presence of
the mecA gene at that moment in time.
The strength of this study is that we used a well-defined
collection of strains with many different strains. Therefore,
we can conclude that this medium is able to detect almost
all MRSA strains that can be found in clinical samples.
There are also several limitations to this study. First, a
relatively high inoculum was used of isolates in pure
culture. In clinical samples there will usually be a relatively
low amount of MRSA and there are other species present as
well. This could lead to more false-negative results in a
clinical evaluation, compared with our results. Also, the
growth of species other than CNS was not evaluated. This
may lead to more false-positive results when Oxoid
Brilliance™ MRSA medium is used on clinical samples.
The performance on patient samples has to be determined
in a prospective clinical evaluation. Kilgour et al. evaluated
Oxoid Brilliance™ MRSA, CHROMagar MRSA and
MRSA ID for the detection of MRSA [17]. A total of 300
freshly collected swabs from a total of 99 patients were
analyzed in this study. When combined results for all media
were analyzed, 269 of the 300 clinical samples were
identified as negative for MRSA. Oxoid Brilliance™
MRSA medium correctly identified the highest number of
samples positive for MRSA (28 out of 31) within 24 h,
yielding a sensitivity of 90.3%. CHROMagar and MRSA
ID required 48 hours incubation and both media yielded
sensitivities of 83.9% (26 out of 31). The highest specificity
was also achieved by Oxoid Brilliance™ MRSA (97.4%),
which yielded only 7 false-positive results. CHROMagar
and MRSA ID yielded 30 and 33 false-positives, pro-
viding specificities of 88.8% and 87.7% respectively.
This small scale clinical study confirms the results of our
study.
In conclusion, Oxoid Brilliance™ MRSA is a sensitive
and a specific tool for differentiation between MSSA and
CNS/MRSA in vitro. Oxoid Brilliance™ MRSA is able to
detect a large number of different MRSA strains after only
20 h of incubation. Therefore, with Oxoid Brilliance™
MRSA, optimal results can be obtained within a day. In
addition, further clinical studies will be performed to
determine the utility of Oxoid Brilliance™ MRSA for the
detection of MRSA directly from clinical samples.
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